Retatrutide

Evidence grade

BHuman trials, not approved for this useScale

Half-life

About 6 days

Schedule

Once weekly, subcutaneous

Maintenance amount

12.00 mg

Vial sizes sold

5 mg, 10 mg, 15 mg, 20 mg, 30 mg

Cost per dose

$119

Where a value is not established in people, this table says so rather than filling the box.

A triple receptor agonist that acts on GLP-1, GIP and glucagon pathways, studied in published clinical research.

Retatrutide hits three receptors at once. GLP-1 and GIP are the two incretin pathways tied to appetite and insulin, and glucagon adds a push on energy expenditure. The GLP-1 and GIP activity curbs appetite and slows how fast the stomach empties, while the glucagon arm is thought to raise metabolic rate on top of that. Working all three at once is why phase 2 weight loss ran deeper than single or dual agonists at comparable points.

Human clinical-trial data from phase 2, with phase 3 programs ongoing.

• Studied for substantial body-weight reduction, up to about 24 percent at 48 weeks in phase 2.
• May improve glycemic control and HbA1c in people with type 2 diabetes.
• Studied for reductions in liver fat and markers of fatty liver disease.
• May lower blood pressure and improve lipid measures alongside weight loss.

• Dose-related nausea, vomiting, diarrhea and constipation are the most common effects.
• Increased heart rate reported at higher doses.
• Reduced appetite can lead to rapid loss of lean mass without protein and resistance training.
• Long-term safety is not yet established given the early trial stage.

A summary of the research, not medical advice. Individual benefits and risks vary, and for some of these compounds the human evidence is still early.

Weeks 1 to 2 tend to bring the first appetite drop and mild GI adjustment. Each step up in dose commonly brings a short return of nausea for a few days. By weeks 5 to 8, dysesthesia and a modest rise in resting heart rate show up more often in reports, both tied to the added glucagon receptor activity.

Drawn from published trial data and how the research community commonly describes this stretch. Not a fixed schedule and not medical advice.

Goal of the protocol. Drive meaningful fat loss and metabolic gains by engaging three incretin and glucagon pathways at once.

Once weekly, subcutaneous. For research reference only, not medical advice.

Mirrors the phase-2 trial escalation; steps rise every four weeks so the gut can adjust. The amount is titrated to the response, so the top step is not always needed, and 12 mg is a high maintenance level.

Higher amounts, more injections. As the weekly total climbs, it is commonly divided into two or more injections across the week, which keeps each shot small and easier to tolerate.

A rough shopping estimate at the maintenance amount. Your real needs shift with your dose and titration.

What a course of Retatrutide actually costs, worked from list price and the amount in the schedule above, plus the whole vials a 12-week run would take.

One supplier listed so far for this compound.

List prices, checked September 4, 2026. Sale pricing is ignored on purpose so the table does not swing week to week. Verify before ordering.

Suppliers are listed alphabetically. We do not rank them by price, because the cheapest vial and the one worth buying are rarely the same thing. The column that matters is the last one, and today most of it reads "none on file", including for Quartz Peptides, which is owned by this site’s editor. See the disclosure and the COA guide.

Lyophilized: Keep the sealed powder cool and dark, near -20 °C where possible, dry and out of light.
Reconstituted: Refrigerate the mixed vial at 2 to 8 °C, use within a few weeks and avoid freeze and thaw.
Let a cold vial reach room temperature before you open it, so it takes on less condensation.